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Background: Little is known about the interplay between n-3 fatty acids and genetic variants for diabetes-related
traits at the genome-wide level. The present study aimed to examine variance contributions of genotype by
environment (GxE) interactions for different erythrocyte n-3 fatty acids and genetic variants for diabetes-related traits
at the genome-wide level in a non-Hispanic white population living in the U.S.A. (n = 820). A tool for Genome-wide
Complex Trait Analysis (GCTA) was used to estimate the genome-wide GxE variance contribution of four
diabetes-related traits: HOMA-Insulin Resistance (HOMA-IR), fasting plasma insulin, glucose and adiponectin.
A GxE genome-wide association study (GWAS) was conducted to further elucidate the GCTA results. Replication
was conducted in the participants of the Boston Puerto Rican Health Study (BPRHS) without diabetes (n = 716).
Results: In GOLDN, docosapentaenoic acid (DPA) contributed the most significant GxE variance to the total
phenotypic variance of both HOMA-IR (26.5%, P-nominal = 0.034) and fasting insulin (24.3%, P-nominal = 0.042). The
ratio of arachidonic acid to eicosapentaenoic acid + docosahexaenoic acid contributed the most significant GxE
variance to the total variance of fasting glucose (27.0%, P-nominal = 0.023). GxE variance of the arachidonic
acid/eicosapentaenoic acid ratio showed a marginally significant contribution to the adiponectin variance (16.0%,
P-nominal = 0.058). None of the GCTA results were significant after Bonferroni correction (P < 0.001). For each trait,
the GxE GWAS identified a far larger number of significant single-nucleotide polymorphisms (P-interaction ≤ 10E-5)
for the significant E factor (significant GxE variance contributor) than a control E factor (non-significant GxE variance
contributor). In the BPRHS, DPA contributed a marginally significant GxE variance to the phenotypic variance of
HOMA-IR (12.9%, P-nominal = 0.068) and fasting insulin (18.0%, P-nominal = 0.033).
Conclusion: Erythrocyte n-3 fatty acids contributed a significant GxE variance to diabetes-related traits at the
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Diabetes has become one of the most common chronic
diseases, with the world prevalence among adults of
6.4% in 2010. It has been estimated that this figure will
increase to 7.7% by 2030, with the absolute number in-
creasing from 285 to 439 million [1]. Type 2 diabetes
(T2D) accounts for more than 90% of diabetes cases and
is characterized by insulin resistance and impaired β-cell
function. Accumulating evidence suggests that T2D is a
result of complex interplay between genetic and environ-
mental factors [2], supporting the notion that a healthier
lifestyle may attenuate the adverse effects of T2D risk
alleles, while an unhealthy lifestyle may augment it.
Dietary n-3 polyunsaturated fatty acids (PUFA) have
been demonstrated in rodents to increase insulin sensi-
tivity through a number of different mechanisms, inclu-
ding anti-inflammatory effects, regulation of circulating
hormones and transcription factors, with effects on
membrane fluidity and improvements in lipid profiles
[3]. In contrast, evidence from observational studies [4]
and clinical trials [5] in humans shows inconsistent asso-
ciation between n-3 PUFA and insulin sensitivity and
T2D. These discrepancies may be attributed partly to
the influence of genotype by environment (GxE) interac-
tions with regard to n-3 PUFA [6,7].
Different n-3 PUFAs may affect insulin sensitivity and
insulin secretion through different mechanisms [3,8]. In
a human randomized controlled trial [9], eicosapen-
taenoic acid (EPA, C20:5n3) and docosahexaenoic acid
(DHA, C22:6n3), the two major n-3 PUFA, showed dif-
ferential effects on glucose metabolism. In addition, the
effect of alpha-linolenic acid (ALA, C18:3n3) on insulin
resistance and T2D differs from that of DHA and EPA
[8]. Thus, it can be postulated that the patterns for the
interplay between n-3 PUFA intake and the genome
varies by type and intake level. However, studies charac-
terizing the GxE interaction of different types of n-3
PUFA with genotypes on T2D-related traits are sparse.
Our previous study demonstrated the importance of
genome-wide GxE interactions in explaining phenotypic
variance of diabetic traits [10]. To date, no published
data are available as to what percentage of total variance
of a given T2D-related trait can be explained by GxE
interactions of individual n-3 PUFA with the whole
genome.
There were three primary objectives of the present
study. One, as erythrocyte membrane n-3 PUFAs are
widely accepted biomarkers for the dietary n-3 PUFA in-
take, we sought to demonstrate the role of the GxE
interaction between different types of erythrocyte n-3
PUFAs and genotypes for the variation of T2D-related
traits at the genome-wide level. Two, we explored the
extent of these GxE variance contributions in a non-
Hispanic white population living in the U.S.A (Table 1).Three, for a given T2D-related trait, our study sought to
identify a corresponding n-3 PUFA that contributed the
most significant GxE variance for each trait. Replication
was conducted in a Puerto Rican population living in the
U.S.A.
Results
Genome-wide GxE variance contribution to the
phenotypic variance of T2D traits
For each trait, GCTA was conducted in GOLDN to assess
the genome-wide variance contribution of genotype by
erythrocyte n-3 PUFAs to total phenotypic variance.
When the GxE was not included in the models, additive
genetic variance contribution for HOMA-IR, fasting insu-
lin, glucose and adiponectin was 23.4% (P-nominal = 4.5 ×
10−4), 17.3% (P-nominal =5.3 × 10−3), 20.6% (P-nominal =
1.9 × 10−3), and 47.5% (P-nominal = 4.5 × 10−13), respec-
tively. When the GxE term was included in the models for
each HOMA-IR and fasting insulin, only DPA contributed
a significant GxE variance to the total phenotypic variance
(26.5% for HOMA-IR, P-nominal = 0.034; 24.3% for fast-
ing insulin, P-nominal = 0.042) (Table 2, Figures 1 and 2).
The additive genetic variance ranged from 12.8% to
21.3% for HOMA-IR depending on the PUFA E factors
(Additional file 1: Table S1), and from 8.6% to 16.0% for
fasting insulin (Additional file 1: Table S2). For fasting
glucose, 27.0% of the total phenotypic variance (P-nom-
inal = 0.023) was explained by the GxE of the ratio of
AA/(EPA +DHA), whereas 13.1% of the variance was
accounted for by additive genetic variance (Table 2,
Additional file 1: Table S3). The contributions of other E
factors to the variance of these traits did not reach statis-
tical significance. None of the GCTA results were signifi-
cant after Bonferroni correction (P < 0.001).
T2D is closely associated with inflammation and is
considered an inflammatory disease [11]. Adiponectin is
well known for its anti-inflammatory effects in several
tissues [12], and recent evidence suggests that it is asso-
ciated with T2D risk [13]. Therefore, we treated fasting
plasma adiponectin as a T2D-related trait and tested the
GxE variance contribution to this trait. For adiponectin,
the AA/ EPA ratio in GOLDN contributed a marginally
significant GxE variance (16.0%, P-nominal = 0.058)
(Table 2, Figures 1 and 2). Although only marginally sig-
nificant, the variance of adiponectin explained by the
additive genetic variance was stable in different GxE
models, ranging from 44.4% to 48.9% (Additional file 1:
Table S4).
To test whether the significant GxE variance contribu-
tion of one E factor was affected by the other E factors, we
used data from GOLDN to pair the nominally significant
E factor with another E factor simultaneously in the
GCTA model (Table 3). For example, for both HOMA-IR
and fasting insulin, we paired DPA with total n-3 PUFA,
Table 1 Population characteristics of the GOLDN study and participants without diabetes in the BPRHS1
GOLDN (n = 820) BPRHS (n = 716)
Mean SD Range (Q1-Q3) Mean SD Range (Q1-Q3)
Age, y 48.9 16 39-62 56.0 7.53 50-61
Female, n (%) 414 (50.5) 501 (70.0)
BMI, kg/m2 28.5 5.5 24.8-31.4 30.6 6.27 26.3-34.0
Energy intake, kJ 8942 5259 5926-10684 10051 5523 6343-11998
Fasting glucose, mmol/L 5.66 1.09 5.11-5.88 5.41 0.61 5.00-5.83
Fasting insulin, pmol/L 97.7 57.4 62.5-111.1 99.7 65.4 57.6-122.2
HOMA-IR 3.61 2.48 2.15-4.2 3.54 2.60 1.92-4.38
Adiponectin, ng/mL 8109 4500 4664-10210 NA NA NA
Erythrocyte n-3 PUFA,% 5.78 1.1 5.00-6.33 6.47 1.37 5.60-7.08
Erythrocyte n-6 PUFA,% 28.2 1.5 27.4-29.2 31.0 2.19 30.1-32.3
Erythrocyte DHA,% 3.01 0.86 2.37-3.46 3.91 1.05 3.23-4.51
Erythrocyte EPA,% 0.52 0.23 0.39-0.59 0.42 0.23 0.29-0.49
Erythrocyte DPA,% 2.11 0.29 1.93-2.27 2.00 0.35 1.79-2.19
Erythrocyte ALA,% 0.14 0.03 0.11-0.16 0.13 0.06 0.09-0.16
Erythrocyte AA,% 13.6 1.1 12.9-14.4 16.5 1.84 15.5-17.6
(n-6)/ (n-3) PUFA 5.06 0.98 4.39-5.74 5.02 1.17 4.30-5.58
AA/ (EPA + DHA) 4.14 1.11 3.36-4.85 4.07 1.13 3.32-4.71
AA/ DHA 4.89 1.41 3.86-5.78 4.51 1.28 3.65-5.24
AA/ EPA 29.6 10.1 22.8-35.9 46.9 19.5 33.6-56.7
1BMI, body mass index; SD, standard deviation; Q, quartile; HOMA-IR, homeostasis model assessment of insulin resistance; PUFA, polyunsaturated fatty acid; DHA,
docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; ALA, alpha-linolenic acid; AA, arachidonic acid.
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tor did not alter the nominally significant GxE variance
contribution of DPA. We paired the AA/(EPA +DHA)
ratio with total n-3/n-6 ratio or EPA +DHA for fasting
glucose, and consistently, the nominally significant contri-
bution of GxE variance of AA/(EPA +DHA) ratio did not
change. However, for adiponectin, the P-values for the
GxE contribution of both EPA and the AA/EPA ratio were
attenuated when they were included in the same model,
due to the high correlation between erythrocyte measures
of AA/EPA and EPA (r = −0.97, P < 0.001). As proxies for
long-term dietary intakes, both factors represented the
same GxE variance for adiponectin.Table 2 GxE variance contribution of erythrocyte n-3 polyuns
GOLDN1
Trait E factor P-nominal
(gxe)2
Vg SE V(gxe)
HOMA-IR DPA 0.034 0.0007 0.0005 0.0015
Fasting insulin DPA 0.042 0.0002 0.0002 0.0006
Fasting glucose AA/ (EPA + DHA) 0.023 0.4518 0.3076 0.9295
Adiponectin AA/ EPA 0.058 0.0200 0.0044 0.0072
1HOMA-IR, HOMA-Insulin Resistance; DHA, docosahexaenoic acid; EPA, eicosapentaeno
acid;Vg, additive genetic variance; V(gxe), variance contributed by GxE interaction; SE,
by GxE interaction; h2 (g + gxe), total heritability. GxE heritability was calculated as the
significant E factors were listed in this table, results of other E factors were listed in the
2P-value (gxe) of GxE interaction was adjusted for age, sex, body mass index, studyGxE interaction of n-3 PUFAs at the genome-wide level
To illustrate further the significance of the contribution of
G×E interaction of PUFA on diabetes-related phenotypes,
a G×E GWAS was conducted in GOLDN for the GCTA-
identified significant E factor using the GWAF (Table 4,
Additional file 2: Table S5). For each trait, we identified
one E factor, which contributed a nominally significant
GxE variance using GCTA, and another E factor, which
contributed a non-significant GxE variance, serving as
control. For HOMA-IR, the GxE GWAS of DPA identi-
fied nine significant SNPs (P-interaction ≤ 1.0 × 10−5), but
just three for ALA, the control E factor. Of greater in-
terest, the GxE GWAS of DPA for fasting insulinaturated fatty acids to four diabetes-related traits in




SE h2 (g + gxe),
% (95% CI)
0.0008 12.8 (0, 30.6) 9.1 26.5 (0, 55.7) 14.9 39.4 (15.9, 62.9)
0.0004 8.6 (0, 25.8) 8.8 24.3 (0, 53.1) 14.7 32.9 (9.87, 55.9)
0.4979 13.1 (0, 30.3) 8.8 27.0 (0, 55.0) 14.3 40.2 (17.6, 62.8)
0.0052 44.4 (27.3, 61.5) 8.7 16.0 (0, 38.3) 11.4 60.4 (40.7, 80.1)
ic acid; DPA, docosapentaenoic acid; ALA, alpha -linolenic acid; AA, arachidonic
standard error; h2 (g), additive genetic heritability; h2 (gxe), heritability explained
GxE variance divided by the total phenotypic variance. Only the nominal
Additional files 1 and 2.
center, energy intake, kinship, and population structure.
Figure 1 GxE variance estimation of n-3 polyunsaturated fatty acids for four diabetes-related traits. The GxE variance is shown as the
percentage of the total phenotypic variance of each trait (heritability). *P < 0.05 indicates significant contribution to total variance. Data are
expressed as mean ± SE.
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E factor (ALA). Similarly, the GCTA-identified significant
E factors for fasting glucose and for adiponectin each
produced more significant SNPs in the GxE GWAS,
compared with their corresponding control E factors.
The number of GxE GWAS-identified SNPs (P-inter-
action ≤ 1.0 × 10−5) for fasting glucose and its significant
E factor AA/(EPA +DHA) was 36, with just a single SNP
identified for the corresponding control E factor. For
adiponectin, there were 13 GxE GWAS-identified SNPs
(P-interaction ≤ 1.0 × 10−5) with the AA/EPA as the sig-
nificant E factor, and 7 for the corresponding control E
factor. For either trait, the QQ-plot drawn based on the
P-values of GxE interaction were slightly above the diag-
onal line for the E factor, which contributed a significantFigure 2 Estimated heritability (%) of diabetes-related traits.
Solid bars depict the heritability based on additive genetic variance.
Unfilled bars represent heritability, as a percentage, arising from the
sum of additive genetic variance and genetic variance by GxE
interaction. GxE heritability was calculated as the GxE variance
divided by the total phenotypic variance. DPA, docosapentaenoic
acid; AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA,
docosahexaenoic acid. Data are expressed as mean ± SE.G×E variance, while for the control E factor, the QQ-plot
aligned well with the diagonal line (Figures 3, 4, 5 and 6).
These QQ-plots confirm the GCTA results.
Replication of GxE variance contribution to the
phenotypic variance of T2D traits in participants of the
BPRHS without diabetes
In the BPRHS, when the GxE term was not included in
the models, the additive genetic variance contribution
for HOMA-IR, fasting insulin and glucose was 8.83%
(P-nominal = 0.02), 6.24% (P-nominal = 0.06) and 13.8%
(P-nominal = 0.006), respectively. Including the GxE
term in the models showed that DPA contributed a
marginally significant GxE variance to the phenotypic
variance of HOMA-IR (12.9%, P-nominal = 0.068) and
fasting insulin (18.0%, P-nominal = 0.033) (Table 5).
However, no significant GxE variance contribution of
the ratio of AA/(EPA + DHA) for fasting glucose va-
riation was observed. For the control E factor (ALA), no
significant GxE variance contribution was observed for
any of the three traits (P-nominal ≥ 0.50).
Discussion
While it is increasingly recognized that the interplay bet-
ween genetic and environmental factors contributes to
T2D risk [2,6,7], inconsistencies among studies often ob-
scure the importance of GxE interactions. The effects of
n-3 PUFAs on chronic disease and related intermediate
phenotypes, for example, have been studied throughout
the last five decades, but discrepancies still exist with re-
gard to outcomes involving human studies [7]. One of
these divergences is the association between n-3 PUFA
and T2D phenotypes [3-5]. Apart from the metho-
dological differences among studies, the influence of
genetic variation is likely an important contributor.
Table 3 Estimation of GxE variance for paired environmental factors on four diabetes-related traits in GOLDN1
Trait E factor h2 (g) SE h2 (gxe) SE P-nominal2
HOMA-IR DPA 0.100 0.099 0.264 0.149 0.034
n-3 PUFA 0.096 0.135 0.225
DPA 0.067 0.103 0.291 0.149 0.023
n-6 PUFA 0.194 0.138 0.069
DPA 0.124 0.099 0.250 0.149 0.044
DHA 0.052 0.134 0.342
Fasting insulin DPA 0.050 0.097 0.242 0.146 0.041
n-3 PUFA 0.141 0.144 0.161
DPA 0.025 0.099 0.261 0.146 0.032
n-6 PUFA 0.243 0.144 0.039
DPA 0.076 0.097 0.228 0.146 0.053
DHA 0.066 0.139 0.312
Fasting glucose AA/ (DHA + EPA) 0.127 0.091 0.264 0.160 0.043
n-6/ n-3 PUFA 0.018 0.150 0.450
AA/ (DHA + EPA) 0.112 0.090 0.279 0.163 0.032
DHA + EPA 0.000 0.150 0.500
Adiponectin AA/ EPA 0.447 0.088 0.096 0.151 0.265
EPA 0.078 0.157 0.318
AA/ EPA 0.419 0.096 0.159 0.115 0.061
AA/ DHA 0.094 0.122 0.210
1For each trait, one significant E factor (significant GxE variance contributor) was simultaneously paired with another E factor into the model, and corresponding
GxE variance for either E factor was estimated in the model. GxE heritability was calculated as the GxE variance divided by the total phenotypic variance. PUFA,
polyunsaturated fatty acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; ALA, alpha-linolenic acid; AA, arachidonic acid;
SE, standard error; h2(g), heritability of additive genetic variance; h2 (gxe), heritability of GxE interaction.
2P-values were adjusted for age, sex, body mass index, study center, energy intake, kinship, and population structure.
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http://www.biomedcentral.com/1471-2164/15/781Previous studies have identified numerous candidate
genes that may have an influence on the effects of n-3
PUFA on T2D or related traits [7]. Recent advances in
GWAS provide the opportunity to explore the influence
of n-3 PUFA GxE on T2D and related traits at the
genome-wide level. In the present study, we used a new
method to illustrate to what extent the GxE of n-3 PUFATable 4 The number of SNPs with P-value <1 × 10−5 based on
Without GxE
Trait2 Main effect E factor GxE3
HOMA-IR 5 DPA S
ALA NS
Fasting insulin 7 DPA S
ALA NS
Fasting glucose 9 AA/ (EPA + DHA) S
ALA NS
Adiponectin 18 AA/ EPA S
n-6 PUFA NS
1PUFA, polyunsaturated fatty acid; DHA, docosahexaenoic acid; EPA, eicosapentaeno
acid; GWAS, genome-wide association study.
2For all these traits, GWAS and GxE GWAS were adjusted for age, sex, body mass in
3The E factor has a significant (S) or non-significant (NS) GxE variance contribution
GxE GWAS.contributed to the variations of T2D-related traits and
to characterize the most important GxE variance con-
tributor among these fatty acids at the genome level.
This approach, for the first time, gives a more detailed
depiction of the interplay between different types of n-3
PUFA and a set of ~590,000 genetic variants, and their
influence on the T2D-related phenotypes. In addition,GxE GWAS in GOLDN1
With GxE









ic acid; DPA, docosapentaenoic acid; ALA, alpha -linolenic acid; AA, arachidonic
dex, study center, energy intake, kinship, and population structure.
to the total phenotypic variance of either diabetes-related trait based on
Figure 3 QQ-plot for HOMA-IR. Two plots on the left are for the main effect and GxE interaction of ALA (control E factor), while two plots on
the right are for the DPA, which contributed a nominal significance to the GxE variance.
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http://www.biomedcentral.com/1471-2164/15/781we were able to distinguish the different GxE patterns
for different n-3 PUFA in red blood cells, which provides
a solid rationale for future research on the impact of dif-
ferent n-3 PUFAs with regard to disease risk and health
maintenance in humans.
Consistent results from rodent models support the
anti-diabetic effects of marine n-3 PUFA [3,8], while in
humans most prospective cohort studies conducted in
Western countries have found null or even positive asso-
ciations between n-3 PUFA and risk of T2D [4,14]. In a
meta-analysis of these cohort studies, we suggested that
genetic and GxE interactions may contribute to these in-
consistent associations in Western populations [4]. Pre-
vious studies, most of which employed a candidate gene
approach, have identified a number of genetic variants
showing GxE with n-3 PUFA on T2D-related traits [6,7].
However, given the powerful regulatory effects of n-3PUFAs, candidate gene approaches can provide only a
narrow view of possible GxE interactions for n-3 PUFAs.
Overcoming this restriction, our genome-wide studies
with GCTA have supplied much information on the
interaction of erythrocyte membrane n-3 PUFAs on
T2D-related traits. We further illustrated the GCTA re-
sults by conducting a GxE GWAS.
Different n-3 PUFAs, such as ALA, EPA, DPA and
DHA, likely exert their health-related effects through
different mechanisms. Among these fatty acids, the
literature regarding the biological effects of DPA is rela-
tively limited [15]. DPA is an intermediate product of
fatty acid metabolism between EPA and DHA, and avail-
able evidence suggests that DPA has both unique as well
as overlapping actions compared to DHA and EPA. In
vivo and in vitro studies [15] have indicated that the bio-
logical effects of DPA mainly stemmed from its effects
Figure 4 QQ-plot for fasting insulin. Two plots on the left are for the main effect and GxE interaction of ALA (control E factor), while two plots
on the right are for the DPA, which contributed a nominal significance to the GxE variance.
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http://www.biomedcentral.com/1471-2164/15/781on eicosanoid production, endothelial cell migration and
gene expression related to lipogenic and inflammatory
genes. However, to our knowledge, studies characterizing
the effects of DPA on T2D-related traits are sparse
and no published reports are available with regard to
the GxE of DPA with genetic variants on T2D traits.
Erythrocyte DPA contributed a nominally significant
GxE variance to the total variance of HOMA-IR and
fasting insulin at the genome-wide level. These results
did not change when we paired DPA with other erythro-
cyte membrane E factors, such as total n-3 PUFA, total
n-6 PUFA or DHA, in the GCTA model. This indicated
that the DPA GxE variance contribution was indepen-
dent of these E factors.
It is known that phenotypic flexibility decreases with
age and onset of pre-clinical conditions. When theenvironment (eg, diet) is perturbed, there is reduced
ability to identify susceptibility variants by GWAS, im-
plying a widespread influence for GxE interactions on
phenotypic variance [16]. Thus, although the two popu-
lations examined here are subject to different envi-
ronmental influences, some of the GxE interactions we
have identified are biologically plausible. For example, one
SNP (rs10074889) near PPARGC1B interacted with DPA
for both HOMA-IR and fasting insulin. PPARGC1B en-
codes peroxisome proliferator-activated receptor (PPAR)
gamma co-activator 1-beta, and is a transcriptional co-
factor contributing to the regulation of fat oxidation,
energy expenditure and glucose metabolism [17]. Further-
more, PPARGC1B expression is down-regulated in skeletal
muscle of T2D patients [18]. Therefore, it can be
postulated that DPA regulates PPARGC1B expression and
Figure 5 QQ-plot for fasting glucose. Two plots on the left are for the main effect and GxE interaction of ALA (control E factor), while two
plots on the right are for the AA/(DHA + EPA), which contributed a nominal significance to the GxE variance.
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http://www.biomedcentral.com/1471-2164/15/781subsequently affects glucose metabolism in an allele-
specific manner. Another example shows that six of the
21 GxE GWAS-identified SNPs for fasting insulin locate
near the CRPP1 and CRP genes, indicating that DPA may
regulate insulin concentrations through an effect on
C-reactive protein and inflammatory pathways [11,19].
However, future research is warranted to characterize the
functions of these identified SNPs and to explore the pre-
cise mechanism for the effect of DPA on insulin resistance
and glucose metabolism.
Other interesting findings include the AA/(EPA +
DHA) ratio contribution of a nominally significant GxE
variance for fasting glucose, and the AA/EPA ratio con-
tribution of a marginally significant GxE variance for
adiponectin in GOLDN, which was not replicated in a
second population. As indicated [20], important roles forthe n-6/n-3 PUFA ratio in coronary artery disease, hyper-
tension and T2D, diseases affected by chronic inflam-
mation. AA is the principle precursor for eicosanoid
production, including 2-series prostaglandins and 4-series
leukotrienes, and these products are highly active agents
of inflammation [21]. In contrast, both EPA and DHA
have anti-inflammatory effects and inhibit the production
of those pro-inflammatory biomarkers [3,21]. Adiponectin
is an anti-inflammatory biomarker, and thus sensitive to
changes in the n-6/n-3 PUFA ratio. Our results indicate
that the n-6/n-3 PUFA ratio affects the genetic suscepti-
bility of fasting glucose and adiponectin. Combining gen-
etic additive variance and GxE variance of the n-6/n-3
ratio explained more phenotypic variation of these two
traits than genetic effects alone. Nevertheless, the results
for adiponectin should be interpreted with caution
Figure 6 QQ-plot for fasting adiponectin. Two plots on the left are for the main effect and GxE interaction of n-6 PUFA (control E factor), while
two plots on the right are for the AA/EPA, which contributed a nominal significance to the GxE variance.
Table 5 Replication of GxE variance contribution of erythrocyte n-3 polyunsaturated fatty acids to diabetes-related
traits in the BPRHS1
Trait E factor P-nominal
(gxe)2




SE h2 (g + gxe),
% (95%CI)
HOMA-IR DPA 0.068 0.0150 0.0300 0.0446 0.0451 4.34 (0, 21.3) 8.66 12.9 (0, 38.4) 13.0 17.1 (0, 38.3)
ALA 0.500 0.0350 0.0350 0 0.019 10.0 (0, 29.2) 9.8 0 (0, 10.5) 5.35 10.0 (0, 24.8)
Fasting insulin DPA 0.033 0.0034 0.0232 0.0531 0.0463 1.16 (0, 16.6) 7.89 18.0 (0, 48.6) 15.6 19.2 (0, 42.2)
ALA 0.500 0.0222 0.0251 0 0.0165 7.45 (0, 23.9) 8.40 0 (0, 10.8) 5.52 7.45 (0, 21.1)
Fasting glucose AA/ (EPA + DHA) 0.252 0.0016 0.0015 0.0004 0.0007 13.3 (0, 38.0) 12.6 3.09 (0, 15.1) 6.14 16.4 (0, 34.8)
ALA 0.500 0.0019 0.0017 0 0.0005 16.2 (0, 43.4) 13.9 0 (0, 9.07) 4.63 16.2 (0, 34.4)
1DPA, docosapentaenoic acid; ALA, alpha -linolenic acid; Vg, additive genetic variance; V(gxe), variance contributed by GxE interaction; SE, standard error; h2 (g),
additive genetic heritability; h2 (gxe), heritability explained by GxE interaction; h2 (g + gxe), total heritability. GxE heritability was calculated as the GxE variance
divided by the total phenotypic variance. ALA was served as a control.
2P-value (gxe) of GxE interaction was adjusted for age, sex, body mass index, energy intake and population structure.
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nectin reached statistical significance.
The GCTA method of estimating the GxE variance con-
tribution enables us to view the pattern of the interplay
between n-3 PUFA and the genome, and to re-examine
the different roles of individual n-3 PUFAs or the related
n-6/n-3 ratio in human health and disease. However, some
limitations are present in this study. First, overestimation
of the genetic and GxE variance may exist given the
family-based nature of the GOLDN population, including
their shared environments within family and causal vari-
ants captured by pedigree, but not by SNPs [22,23]. This is
also the reason why the estimates of heritability are gener-
ally higher in GOLDN than in BPRHS, a population com-
prised of unrelated individuals. Second, the sample size of
the present study is moderate. Studies with larger sample
size and populations of different ethnicities, but equally
deeply phenotyped, are needed to confirm our results.
Third, none of our primary GCTA results was significant
after Bonferroni correction for multiple testing. However,
the Bonferroni correction is very conservative and may
not be the most appropriate correction method to apply in
this circumstance. Nevertheless, our results from GCTA
were further confirmed by a GxE GWAS and replicated in
part (by GCTA) in a second population.
Conclusions
We used a GCTA method to explore the GxE variance
contribution of erythrocyte membrane n-3 PUFA to the
variation of T2D-related traits at the genome-wide level.
We demonstrated that, at the genome-wide level, different
types of n-3 PUFA can contribute different GxE variances
to the same phenotype, and the same n-3 PUFA contrib-
utes different amounts of GxE variances to different phe-
notypes. These results indicate the importance of the GxE
of n-3 PUFAs for major diabetes traits, and also suggest
the extent to which these GxE interactions contribute to
the variation of each trait. Our results have important
implications for public health research in that long-chain
n-3 PUFAs have been accepted widely as dietary supple-
ments around the world, while the effects of n-3 PUFAs
on major chronic diseases, such as T2D and cardio-
vascular disease, remain inconclusive. The genome-wide
influence of n-3 PUFA GxE explains some of these incon-
sistencies, and future dietary recommendations should
consider the effects of genetic variation, especially as per-
sonalized nutrition gains acceptance. Furthermore, a
mechanism for the unique function of each individual n-3
PUFA warrants more comprehensive research.
Methods
Subjects
The Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) Study was designed to examine genetic factorsthat regulate dietary and fenofibrate responses, and the
study details have been described [24,25]. Caucasian fam-
ilies with at least 2 siblings of 3-generations were recruited
from two centers of the National Heart, Lung, and Blood
Institute Family Heart Study in Minneapolis, MN, and Salt
Lake City, UT. Exclusion criteria include age < 18 years,
fasting triglycerides > 16.5 mmol/L, recent history of myo-
cardial infarction, liver, kidney, pancreas, or gall bladder
disease, history of malabsorption of nutrients, current use
of insulin, abnormal renal or hepatic function, and preg-
nancy or nursing in women. The current study examined
the data of T2D-related traits collected at the baseline of
the GOLDN population. The original sample size for the
GOLDN study was approximately 1200, while completed
biochemical data were available from 1118 individuals.
Genome-wide genotyping data was obtained from 820
subjects. Baseline characteristics of the 820 GOLDN par-
ticipants are shown in Table 1. All participants gave in-
formed consent. The study protocol was approved by the
Institutional Review Boards at the University of Alabama,
University of Minnesota, University of Utah, and Tufts
University.
Replication was conducted in the Boston Puerto Rican
Health Study (BPRHS), a longitudinal cohort study of
stress, nutrition, health, and aging in Puerto Ricans living
in the Boston metropolitan area [26]. Erythrocyte fatty
acid and genome-wide genotyping data were obtained
from 1198 participants. Of these, 716 participants without
diabetes were included in the final analysis (482 with
diabetes were excluded) as the variance contribution ana-
lysis may be influenced by diabetes status or anti-diabetes
medication (Table 1). All participants gave informed
content. The study protocol was approved by the Institu-
tional Review Boards at Tufts University and Northeastern
University.
Biochemical measurement and erythrocyte fatty acid
determination
For GOLDN, venous blood was drawn after an over-
night fast. Measurements of fasting plasma glucose,
insulin, and adiponectin have been described [27,28].
For the BPRHS, fasting serum glucose and insulin
were measured as previously described [29]. For both
GOLDN and BPRHS, erythrocyte isolation and fatty
acid extraction followed standard procedures [30,31],
and the final values of fatty acid methylesters were
expressed as percentage of total fatty acids. Homeostasis
model assessment of insulin resistance (HOMA-IR)
(calculated as fasting insulin*fasting glucose/22.5) was
used to assess insulin resistance. All glucose-related
traits, including HOMA-IR, fasting insulin, glucose
and adiponectin (GOLDN only) were Box-Cox [32] or
log transformed to achieve normal distribution before
analysis.
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For GOLDN, genomic DNA was extracted and purified as
described previously [33]. Affymetrix Genome-Wide
Human SNP Array 6.0 (CA, USA) and the Birdseed calling
algorithm were used to conduct genome-wide genotyping.
A total number of 590,000 SNPs were selected for the
genome-wide analysis in the present study according
to the following criteria: call rate ≥96%, minor allele
frequency (MAF) ≥5%, P-value ≥10−6 for the Hardy-
Weinberg equilibrium (HWE) test, negligible Mendelian
error within one family [24]. Briefly, SNPs were excluded
if they were monomorphic or had a call rate < 96%. SNPs
were also excluded based on the number of families with
Mendel error: for MAF ≥20%, if errors were present in >3
families; for 20% >MAF ≥10%, if errors were present in >2
families; for 10% >MAF ≥5%, if errors were present in >1
family; and for MAF <5%, if any errors were present [24].
For the BPRHS, DNA was obtained from blood samples
using QIAamp DNA Blood Mini Kits (Qiagen). GWAS
genotyping was conducted using Affymetrix’s AxiomGe-
nome-Wide LAT Array, which was designed especially for
Hispanic populations and contains probe sets to genotype
817,810 SNPs. The Genome-Wide genotype was called
and QC using Affymetrix® Power Tools (APT), Geno-
typing Console (GTC), and R, following the standard pro-
tocols – Best Practices provided by the vender. Based on
the criteria of SNPolisher, 804,947 SNPs passed general
QC. Among them, 717,275 autosomal SNPs that met the
following criteria: call rate ≥97%, minor allele frequency
(MAF) ≥1%, P-value of Hardy-Weinberg Equilibrium
(HWE) ≥10−6, were used in current study. To estimate
population structure, 50,704 SNPs were further selected
based on following criteria: MAF ≥5%, and pair-wise link-
age disequilibrium R square ≤0.1. Using principle compo-
nents analysis, as implemented in SVS (Golden Helix Inc.,
Bozeman, MT), we selected the first major principal com-
ponent eigenvalue to present the population structure
based on the scree plot. This was included in models for
all the analyses to adjust for population structure.
Genome-wide variance contribution of genotype by
erythrocyte n-3 PUFA interaction to T2D-related traits in
GOLDN and replication in BPRHS
For GOLDN, GxE variance contribution to the total
variance of T2D-related traits was estimated using a tool
for Genome-wide Complex Trait Analysis (GCTA) [34].
Within GCTA, the GxE interaction and main effects of
genetic factors were treated as random effects in the
model, with the main effects of E factors as fixed effects,
while adjusting for potential confounders, including age,
sex, body mass index, study center, energy intake, kin-
ship and population structure. A “–gxe” option was used
to estimate the variance contribution of GxE interaction
in the GCTA. Briefly, GCTA was run in a Linuxcomputer environment with the following steps: 1) gene-
rate three files (bed, bim and fam) for the GWAS geno-
types using PLINK; 2) A “–make-grm” option was used to
generate grm.gz and grm.id files; 3) prepare a phenotype
file for each trait and a covariate file; 4) estimate the GxE
variance contribution using a “-gxe” option. Based on the
method of the GCTA power calculation by Visscher et al.
[35], we calculated the power to estimate heritability
greater than zero (h2 ≥ 0.2) to be 94% for GOLDN with
family structures (n = 820, variance of the SNP-derived
genetic relationships = 0.00093), 44% for the BPRHS par-
ticipants without family structure (n = 716, variance of the
SNP-derived genetic relationships = 0.00032).
An E factor is the environmental term in the GxE inter-
action, in this case the concentration of a particular PUFA
in the erythrocyte membrane as a proxy for long-term
dietary intake. Principle components analysis was used to
calculate the population structure using SVS (Golden
Helix Inc., Bozeman, MT.) [36,37], and three key principle
components were included in the model as covariates.
GxE heritability was calculated as the GxE variance
divided by the total phenotypic variance. In the GCTA,
four T2D-related traits, including HOMA-IR, fasting insu-
lin, glucose and adiponectin, were treated as phenotypes
for the estimation of variance contribution. Eleven n-3
PUFAs or related E factors were available to this study:
total n-3 PUFA, n-6 PUFA, ALA, EPA, DHA, EPA +
DHA, docosapentaenoic acid (DPA, C22:5n3), arachidonic
acid (AA, C20:4n6)/EPA, AA/DHA, AA/(EPA +DHA)
and total n-6/n-3 PUFA ratio. Each E factor was catego-
rized into quartiles for data analysis. As the ratio of n-6 by
n-3 fatty acids was suggested to play an important role in
the development of many chronic diseases [38], and dif-
ferent n-3 fatty acids may exert differential effects on the
biological system [8,15], we selected combinations of
different n-6 by n-3 fatty acid ratios as the E factors.
Bonferroni correction was employed to correct for mul-
tiple testing. In the GCTA analysis, the number of mul-
tiple tests was 44 (4 × 11), thus a P-value < 0.001 was
considered as significant after correction (0.05/ (4 × 11)).
For BPRHS, GCTA was conducted to replicate the sig-
nificant variance contribution produced by the GOLDN
population. An E factor with non-significant variance
contribution in the GOLDN was selected as a control
for each trait. The potential confounders in BPRHS were
age, sex, body mass index, energy intake and population
structure. Principle components analysis was used to es-
timate the population structure using SVS (Golden Helix
Inc., Bozeman, MT.) [36,37].
GxE genome-wide association study (GWAS) in GOLDN
Genome-wide GxE interaction analysis was conducted
using linear mixed effects model (LME) under an addi-
tive genetic model in a GWAF package [39] in R, version
Zheng et al. BMC Genomics 2014, 15:781 Page 12 of 13
http://www.biomedcentral.com/1471-2164/15/7812.15.0. This method treats all genotypes and GxE interac-
tions as fixed effects and the family relationship as a ran-
dom effect through the kinship matrix. Quantile-quantile
(QQ) plots were drawn in R to characterize the extent to
which the observed GxE P-values follow the expected
(null) distribution [40]. A P-value <1.0 × 10−5was con-
sidered significant, as this threshold is generally recom-
mended for discovery in GWAS.
Additional files
Additional file 1: Table S1. GxE Variance contribution of erythrocyte
n-3 polyunsaturated fatty acids to HOMA-IR. Table S2. GxE Variance
contribution of erythrocyte n-3 polyunsaturated fatty acids to fasting
insulin. Table S3. GxE Variance contribution of erythrocyte n-3 polyunsaturated
fatty acids to fasting glucose. Table S4. GxE Variance contribution of erythrocyte
n-3 polyunsaturated fatty acids to adiponectin.
Additional file 2: Table S5. SNP list identified from GxE GWAS for
diabetes traits in GOLDN population.
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